ProfileGDS5678 / 1420219_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 72% 74% 65% 72% 74% 71% 72% 70% 66% 68% 71% 72% 76% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8923375
GSM967853U87-EV human glioblastoma xenograft - Control 24.6475772
GSM967854U87-EV human glioblastoma xenograft - Control 34.8983774
GSM967855U87-EV human glioblastoma xenograft - Control 43.9299865
GSM967856U87-EV human glioblastoma xenograft - Control 54.5474572
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.772774
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4643371
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6255972
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3505670
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9902166
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1368
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.4830571
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.6023372
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.0948676